Trial · NCT01440946
Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B
NCT01440946, Phase 3, Completed, Bioverativ Therapeutics Inc.; results first posted 2015-06-18
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B. Trials, record NCT01440946. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01440946
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B
- NCT number
- NCT01440946
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 30 participants, actual
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Conditions
- Hemophilia B
- Interventions
- rFIXFc, FIX
- First posted
- 2011-09-27
- Last updated
- 2020-12-19
- Other registries' IDs
- eudract:2011-003076-36
- Results first posted
- 2015-06-18
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurence of Factor IX (FIX) Inhibitor Development | Up to 50 weeks +/- 7 days, or up to 50 EDs if reached prior to Week 50 | An inhibitor test result ≥ 0.6 Bethesda units (BU)/mL, confirmed on 2 separate samples drawn 2 to 4 weeks apart, was considered positive. Both tests were to be performed by the central laboratory using the Nijmegen-modified Bethesda Assay. Incidences were summarized for any positive inhibitor for participants with ≥ 50 exposure days (EDs) to rFIXFc. In addition, the incidence for all participants, regardless of their EDs to rFIXFc, was also summarized. An exact 95% CI for the proportion of participants with a confirmed inhibitor was calculated using the Clopper-Pearson exact method for a binomial proportion. |
| Secondary | Annualized Bleeding Rate | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Annualized bleeding rate = (number of bleeding episodes during the efficacy period / total number of days during the efficacy period)\*365.25. The efficacy period begins with the first prophylactic dose of rFIXFc and ends with the last dose (for prophylaxis or a bleeding episode). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. A bleeding episode started from the first sign of bleeding and ended no more than 72 hours after the last treatment for the bleeding episode, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. Any injection to treat the bleeding episode taken more than 72 hours after the preceding one was considered the first injection to treat a new bleeding episode at the same location. Any bleeding at a different location was considered a separate bleeding episode, regardless of time from last injection. |
| Secondary | Annualized Joint Bleeding Rate (Spontaneous) | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Annualized bleeding rate for spontaneous joint bleeding episode=(number of bleeding episodes meeting those criteria during the efficacy period/total number of days during the efficacy period)\*365.25. Efficacy period begins with the first prophylactic dose of rFIXFc and ends with the last dose (for prophylaxis or a bleeding episode). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. A bleeding episode started from the first sign of bleeding and ended ≤ 72 hours after the last treatment for the bleeding episode, within which any symptoms of bleeding at the same location or injections ≤ 72 hours apart were considered the same bleeding episode. Any injection to treat the bleeding episode taken \> 72 hours after the preceding 1 was considered the first injection to treat a new bleeding episode at the same location. Any bleeding at a different location was considered a separate bleeding episode, regardless of time from last injection. |
| Secondary | Participant Assessment of Response to Injections to Treat a Bleeding Episode | Up to 50 weeks +/- 7 days | Participant's assessment of the response (provided by the caregiver) to the first rFIXFc injection for each bleeding episode. Percentages were based on the number of bleeding episodes for which a response was provided for the first injection, using the following 4-point scale: excellent=abrupt pain relief and/or improvement in signs of bleeding within approximately 8 hours after the initial injection; good=definite pain relief and/or improvement in signs of bleeding within approximately 8 hours after an injection, but possibly requiring more than one injection after 24 to 48 hours for complete resolution; moderate=probable or slight beneficial effect within 8 hours after the initial injection and requiring more than one injection; no response=no improvement, or condition worsened, within approximately 8 hours after the initial injection. |
| Secondary | Physician's Global Assessment of the Participant's Response to His rFIXFc Regimen | Up to 50 weeks +/- 7 days | Investigators assessed each participant's response to his rFIXFc regimen using a 4-point scale: excellent=bleeding episodes responded to ≤ the usual number of injections or ≤ the usual dose of rFIXFc or the rate of breakthrough bleeding during prophylaxis was ≤ that usually observed; effective=most bleeding episodes responded to the same number of injections and dose, but some required more injections or higher doses, or there was a minor increase in the rate of breakthrough bleeding; partially effective=bleeding episodes most often required more injections and/or higher doses than expected, or adequate breakthrough bleeding prevention during prophylaxis required more frequent injections and/or higher doses; ineffective=routine failure to control hemostasis, or hemostatic control required additional agents. Percentages are based on the total number of responses; multiple responses per participant are counted. |
| Secondary | Annualized rFIXFc Consumption by Type of Injection | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Annualized consumption of rFIXFc for prevention of bleeding (prophylactic), treatment of bleeding, and other rFIXFc injections. Consumption is calculated for the efficacy period. The efficacy period began with the first prophylactic dose of rFIXFc and ended with the last dose (regardless of the reason for dosing). Surgery/rehabilitation and PK evaluation periods were not included in the efficacy period. Annualized consumption = (total IU/kg of study treatment received during the efficacy period / total number of days during the efficacy period)\*365.25. Participants who did not have a particular injection type are counted as having zero injections for that type. |
| Secondary | Number of Days From the Last Prophylaxis Injection to a Spontaneous Bleeding Episode | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | The number of days from the last prophylaxis injection to the onset of a new spontaneous bleeding episode, analyzed across all evaluable bleeding episodes per participant and per episode, based on the efficacy period. Evaluable bleeding episodes are those for which both a date and time are available for both the onset of the bleeding episode and the previous prophylactic injection. The efficacy period begins with the first prophylactic dose of rFIXFc and ends with the last dose (for prophylaxis or a bleeding episode). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. For 'Per participant' values, the number of days from the last prophylactic injection to a spontaneous bleeding episode is averaged across all evaluable spontaneous bleeding episodes per participant. |
| Secondary | Number of Injections Required for Resolution of a Bleeding Episode | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | The number of injections required to resolve a bleeding episode per participant and per episode, based on the efficacy period. The efficacy period begins with the first prophylactic dose of rFIXFc and ends with the last dose (for prophylaxis or a bleeding episode). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. All injections given from the initial sign of a bleeding episode, until the last date/time within the bleeding episode window are counted. The resolution of a bleeding episode is defined as no sign of bleeding following injection for the bleeding episode. For 'Per participant' values, the number of injections required to resolve each bleeding episode is averaged across all bleeding episodes per participant. |
| Secondary | Total Dose Required for Resolution of a Bleeding Episode | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | The total dose required to resolve a bleeding episode per participant and per episode, based on the efficacy period. The efficacy period begins with the first prophylactic dose of rFIXFc and ends with the last dose (for prophylaxis or a bleeding episode). Surgery/rehabilitation periods and PK evaluation periods are not included in the efficacy period. For 'Per bleeding episode' values, for each bleeding episode, the total dose is the sum of the doses (IU/kg) administered across all injections given to treat that bleeding episode. For 'Per participant' values, the total dose (IU/kg) used to resolve each bleeding episode is averaged across all bleeding episodes per participant. |
| Secondary | Maximum Plasma Activity (Cmax; One-stage Activated Partial Thromboplastin Time [aPTT] Clotting Assay) | Baseline (28±7 days before Day 1) Prestudy FIX Dosing: predose; 30±5 min, 3 hrs±30 min, 10±2 hrs, 24±3 hrs, 48±4 hrs postdose. Day 1 rFIXFc Dosing: predose; 30±5 min, 3 hrs ±30 min, 10±2 hrs, 24±3 hrs, 72±7 hrs, 120±12 hrs, 168±16 hrs postdose. | Cmax: maximum plasma FIX activity during a dosing interval. The values for Cmax were adjusted to the nominal dose of 50 IU/kg. The 95% confidence interval on the geometric mean is based on the t-statistic back-transformed from the log scale. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Occurence of Factor IX (FIX) Inhibitor Development | Up to 50 weeks +/- 7 days, or up to 50 EDs if reached prior to Week 50 | Safety Analysis Set: participants who received at least 1 dose of prestudy FIX, or at least 1 dose of rFIXFc; n=number of participants with given number of EDs who had a valid inhibitor test. | percentage of participants | NUMBER |
| SECONDARY | Annualized Bleeding Rate | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Full Analysis Set: participants who received at least 1 dose of rFIXFc; based on the number of participants whose efficacy period was of at least 1 day in duration. | bleeding episodes per participant per yr | MEDIAN |
| SECONDARY | Annualized Joint Bleeding Rate (Spontaneous) | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Full Analysis Set: participants who received at least 1 dose of rFIXFc; based on the number of participants whose efficacy period is of at least 1 day in duration. | bleeding episodes per participant per yr | MEDIAN |
| SECONDARY | Participant Assessment of Response to Injections to Treat a Bleeding Episode | Up to 50 weeks +/- 7 days | Full Analysis Set: participants who received at least 1 dose of rFIXFc and had ≥ 1 bleeding episode; based on the number of injections with an evaluation. | percent of 1st injections w/ a response | NUMBER |
| SECONDARY | Physician's Global Assessment of the Participant's Response to His rFIXFc Regimen | Up to 50 weeks +/- 7 days | Full Analysis Set: participants who received ≥ 1 dose of rFIXFc; based on the number of responses. | percentage of responses | NUMBER |
| SECONDARY | Annualized rFIXFc Consumption by Type of Injection | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Full Analysis Set: participants who received at least 1 dose of rFIXFc. | IU/kg rFIXFc per year | MEAN |
| SECONDARY | Number of Days From the Last Prophylaxis Injection to a Spontaneous Bleeding Episode | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Full Analysis Set: participants who received at least 1 dose of rFIXFc; number of participants and number of episodes were determined for participants with at least 1 evaluable spontaneous bleeding episode. | days | MEDIAN |
| SECONDARY | Number of Injections Required for Resolution of a Bleeding Episode | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Full Analysis Set: participants who received at least 1 dose of rFIXFc; number of participants and number of episodes were determined for participants with at least 1 evaluable bleeding episode. | injections | MEDIAN |
| SECONDARY | Total Dose Required for Resolution of a Bleeding Episode | Up to 50 weeks +/- 7 days (efficacy period as defined in description) | Full Analysis Set: participants who received at least 1 dose of rFIXFc; number of participants and number of episodes were determined for participants who had complete information on the dose administered to treat a bleeding episode. | IU/kg | MEDIAN |
| SECONDARY | Maximum Plasma Activity (Cmax; One-stage Activated Partial Thromboplastin Time [aPTT] Clotting Assay) | Baseline (28±7 days before Day 1) Prestudy FIX Dosing: predose; 30±5 min, 3 hrs±30 min, 10±2 hrs, 24±3 hrs, 48±4 hrs postdose. Day 1 rFIXFc Dosing: predose; 30±5 min, 3 hrs ±30 min, 10±2 hrs, 24±3 hrs, 72±7 hrs, 120±12 hrs, 168±16 hrs postdose. | PK Analysis Set: all participants with adequate PK data, defined as complete and evaluable PK samples through 168 hours after rFIXFc dosing. Complete means the availability of the 168-hour sample and at least enough other samples to allow for all the PK parameters to be estimated. | IU/dL | GEOMETRIC_MEAN |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 outcomesResults by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Occurence of Factor IX (FIX) Inhibitor Development | Participants < 6 Years Old | Participants with ≥ 50 EDs; n=10, 13, 23 | 0 | 95% Confidence Interval 0 to 30.85 | percentage of participants |
| Occurence of Factor IX (FIX) Inhibitor Development | Participants 6 to < 12 Years Old | Participants with ≥ 50 EDs; n=10, 13, 23 | 0 | 95% Confidence Interval 0 to 23.16 | percentage of participants |
| Occurence of Factor IX (FIX) Inhibitor Development | Total | Participants with ≥ 50 EDs; n=10, 13, 23 | 0 | 95% Confidence Interval 0 to 14.25 | percentage of participants |
| Occurence of Factor IX (FIX) Inhibitor Development | Participants < 6 Years Old | All participants regardless of # of EDs;n=15,15,30 | 0 | 95% Confidence Interval 0 to 21.8 | percentage of participants |
| Occurence of Factor IX (FIX) Inhibitor Development | Participants 6 to < 12 Years Old | All participants regardless of # of EDs;n=15,15,30 | 0 | 95% Confidence Interval 0 to 21.8 | percentage of participants |
| Occurence of Factor IX (FIX) Inhibitor Development | Total | All participants regardless of # of EDs;n=15,15,30 | 0 | 95% Confidence Interval 0 to 11.57 | percentage of participants |
| Annualized Bleeding Rate | Participants < 6 Years Old | 1.09 | Inter-Quartile Range 0.00 to 2.90 | bleeding episodes per participant per yr | |
| Annualized Bleeding Rate | Participants 6 to < 12 Years Old | 2.13 | Inter-Quartile Range 0.00 to 4.17 | bleeding episodes per participant per yr | |
| Annualized Joint Bleeding Rate (Spontaneous) | Participants < 6 Years Old | 0.00 | Inter-Quartile Range 0.00 to 1.2 | bleeding episodes per participant per yr | |
| Annualized Joint Bleeding Rate (Spontaneous) | Participants 6 to < 12 Years Old | 0.00 | Inter-Quartile Range 0.00 to 2.2 | bleeding episodes per participant per yr |
1 to 10 of 60Source ClinicalTrials.gov
See all 60 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants < 6 Years Old | 15 | |
| Overall Study | STARTED | Participants 6 to < 12 Years Old | 15 | |
| Overall Study | COMPLETED | Participants < 6 Years Old | 13 | |
| Overall Study | COMPLETED | Participants 6 to < 12 Years Old | 14 | |
| Overall Study | NOT COMPLETED | Participants < 6 Years Old | 2 | |
| Overall Study | NOT COMPLETED | Participants 6 to < 12 Years Old | 1 |
Source ClinicalTrials.gov
Adverse events138
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Haemorrhagic Anaemia | Blood and lymphatic system disorders | Participants < 6 Years Old | 0 | 15 | |
| other | Haemorrhagic Anaemia | Blood and lymphatic system disorders | Participants 6 to < 12 Years Old | 1 | 15 | |
| other | Iron Deficiency Anaemia | Blood and lymphatic system disorders | Participants < 6 Years Old | 1 | 15 | |
| other | Iron Deficiency Anaemia | Blood and lymphatic system disorders | Participants 6 to < 12 Years Old | 0 | 15 | |
| other | Ear Pain | Ear and labyrinth disorders | Participants < 6 Years Old | 1 | 15 | |
| other | Ear Pain | Ear and labyrinth disorders | Participants 6 to < 12 Years Old | 1 | 15 | |
| other | Cheilitis | Gastrointestinal disorders | Participants < 6 Years Old | 1 | 15 | |
| other | Cheilitis | Gastrointestinal disorders | Participants 6 to < 12 Years Old | 0 | 15 | |
| other | Constipation | Gastrointestinal disorders | Participants < 6 Years Old | 2 | 15 | |
| other | Constipation | Gastrointestinal disorders | Participants 6 to < 12 Years Old | 0 | 15 |
1 to 10 of 138Source ClinicalTrials.gov
See all 138 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants < 6 Years Old | ||
| Total, all-cause mortality | Participants 6 to < 12 Years Old | ||
| Total, other adverse events | Participants < 6 Years Old | 12 | 15 |
| Total, other adverse events | Participants 6 to < 12 Years Old | 14 | 15 |
| Total, serious adverse events | Participants < 6 Years Old | 3 | 15 |
| Total, serious adverse events | Participants 6 to < 12 Years Old | 1 | 15 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Participants < 6 Years Old vs Participants 6 to < 12 Years Old: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01440946
GET https://conductscience.org/api/trials/v1/NCT01440946/results?page=2